Spots Global Cancer Trial Database for Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Official Title: Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia

Study ID: NCT02093403

Conditions

Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

Interventions

decitabine

selinexor

pharmacological study

laboratory biomarker analysis

Study Description

Brief Summary: This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and Selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of Selinexor (KPT-330) in combination with decitabine in patients with acute myeloid leukemia (AML). II. To define the specific toxicities, maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of this combination. III. To determine the Recommended Phase 2 Dose (RP2D) of this combination. SECONDARY OBJECTIVES: I. To determine the overall response rate (ORR). II. To determine the rate and duration of complete remission (CR) +/- hematological recovery of KPT-330 plus decitabine in AML. III. To conduct pharmacodynamic studies by measuring the effect of this chemotherapy combination on the kinome, micronome and epigenome. OUTLINE: This is a dose-escalation study of selinexor. INDUCTION: Patients receive decitabine intravenously (IV) over 1 hour on days 1-10 and Selinexor orally (PO) on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and Selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.